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Whether ischemic preconditioning (IP) reduces ischemia/reperfusion (I/R) injury in human normal and fatty livers remains
controversial. We compared two independent groups of liver donor transplants with versus without steatosis to evaluate IP
consequences. Liver donors with (n¼22) or without (n¼28) steatosis either did or did not undergo IP before graft retrieval.
Clinical data from the recipients, as well as histological and immunohistological characteristics of post-reperfusion biopsies
were analyzed. Incidence of post-reperfusion necrosis was increased (10/10 versus 9/14, respectively; Po0.05) and the clinical
outcome of recipients was worse for non-IP steatotic liver grafts compared with non-IP non-steatotic grafts. IP signiﬁcantly
lowered the transaminase values only in patients receiving a non-steatotic liver. An increased expression of beclin-1 and LC3,
twopro-autophagicproteins,tendedtodecreasetheincidenceofnecrosis(P¼0.067)inIPsteatoticliverscomparedwithnon-IP
steatotic group. IP decreasedthe incidence of acute and chronic rejection episodes in steatotic livers (2/12 versus 6/10; P¼0.07
and 2/12 versus 7/10; Po0.05, respectively), but not in non-steatotic livers. Thus, IP may induce autophagy in human steatotic
liver grafts and reduce rejection in their recipients.
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In steatotic livers, hepatocytes cell death and inﬂammatory
response have a great impact in both surgical and medical
context.
1,2 Indeed, steatoticlivers are more sensitive to ischemia–
reperfusion (I/R) injury.
3,4 Operative mortality rate associated with
steatosis after major liver resection has been reported as high as
1 4%co mp ar edwi t h2%fo rh ea lt h yli v er s.
4 Steatoticliver grafts
are more frequently used in the context of transplantation and
they are associated with a primary non-function rate of 60%
compared with o5% for non-steatotic grafts.
5,6 Therefore,
developing protective strategies to minimize the adverse effects
of I/R injury in steatotic livers is of paramount importance.
Ischemic preconditioning (IP), ﬁrst described in the heart by
Murry et al.,
7 consists of brief periods of vascular occlusion
which confer protection against subsequent I/R via endogen-
ous protective mechanisms. In the liver, IP was shown to
lower transaminase levels and reduce endothelial cell injury.
8
This protection has been linked to various mechanisms, such
as decreased apoptosis,
9 preservation of the ATP content in
liver tissue,
8,10 or overproduction of pro-survival and anti-
inﬂammatory proteins.
11
The beneﬁcial effects of IP in human liver hepatectomy,
associated with warm and short ischemia have been
demonstrated in young patients and patients with liver
steatosis.
8 In liver transplantation, some previous studies
have demonstrated controversial results of the role of IP on
liver grafts. Our group was the ﬁrst to show a signiﬁcant
decrease in transaminase levels after IP counterbalanced by
decreasedearlyfunctionofthegraft.
12Jassemetal.
13founda
signiﬁcant reduction of transaminase levels in IP patients
compared with non-IP patients in the post-operative period,
whereas Koneru et al.,
14 found a paradoxal effect of higher
transaminase peak in IP livers. These studies have shown
that steatosis was a signiﬁcant worsening parameter for I/R
injuries, although none of them have speciﬁcally studied the
role of IP on steatotic or non-steatotic livers. Recently,
Franchello et al.
15 compared normal livers with marginal
livers, including mostly livers from donors over the age of 60.
They have shown that IP reduced the AST and ALT mean
levels 5min after reperfusion during the ﬁrst 3 operative days.
Interestingly, they also observed that IP induced a lower rate
of hepatocyte cell death as assessed by TUNEL assay, the
apoptotic index being higher in marginal livers compared with
normal livers outside the context of preconditioning. There-
fore, our objective was to focus on macro–microvesicular
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www.nature.com/cddissteatotic livers that underwent cold ischemia, and preserva-
tion during liver transplantation to determine whether and how
IP could inﬂuence cell death and clinical efﬁcacy or safety in
the recipients.
Results
Donor, recipient and intraoperative data. In all, 22 donor
livers out of 50 showed steatosis. Steatosis was globally
graded as mild (o30% of steatotic hepatocytes) in 16 livers
and moderate in 6 (steatotic hepatocytes 430% but o60%).
In all, 17 livers showed mixed macro and microvesicular
steatosis, with macrovesicular ranging from 41t or30%
and microvesicular ranging from 45t or50%. Three
steatotic liver grafts showed only microvesicular steatosis
ranging from 20 to 40% of hepatocytes. Two others showed
only macrovesicular steatosis affecting 10% of hepatocytes.
There was no signiﬁcant difference in distribution of age and
hospitalization stay for graft donors before transplantation
between groups (Table 1). No signiﬁcant differences were
observed in recipients with regard to age, gender or initial
disease before transplantation (Table 2), nor for surgical
parameters (Table 3).
Clinical and histological outcomes in patients receiving
non-steatotic or steatotic allografts without IP. When
comparing the two groups of patients who did not undergo IP,
higher mean values in both peak and day 5 levels of AST and
ALT were observed in recipients of steatotic grafts compared
with recipients of non-steatotic grafts, although these
differences were not statistically signiﬁcant because of high
inter-patient variability (Table 4). Mean AST and ALT peaks
were 862 and 728IU/l in patients receiving steatotic grafts,
whereas they were 458 and 577IU/l in patients receiving
non-steatotic grafts. AST and ALT day 5 levels were 139 and
423IU/l in patients receiving steatotic grafts and 79 and
247IU/l in patients receiving non-steatotic grafts (Table 4).
Levels of serum bilirubin at day 7 were signiﬁcantly higher in
steatotic livers compared with non-steatotic livers, whereas
no difference was observed in PT levels (Table 4). No
signiﬁcant differences in post-transplantation intensive care
unit stay (12 days versus 11 days) or total hospitalization stay
Table 1 Allografts characteristics before transplantation in IP and non-IP donors
Non-steatotic allografts Steatosic allografts
Variable
IP (n¼14)
group I
Non-IP (n¼14)
group II
IP (n¼12)
group III
Non-IP (n¼10)
group IV
P-value
I versus II
a
P-value
III versus IV
a
P-value
I versus III
a
P-value
II versus IV
a
Age of donor (years) 47.9±13.6 50.1±12.1 50.5±8.4 54.7±10.3 0.65 0.30 0.57 0.34
Donor hospitalization
(days in intensive care unit)
1.9±1.1 1.8±1.0 2.1±1.3 1.6±0.9 0.67 0.38 0.73 0.77
Body mass index 21.7±3.3 23.7±2.9 25.1±3.7 24.9±2.3 0.11 0.87 0.02 0.29
Histology before reperfusion
Necrosis
Absent 12/14 13/14 12/12 9/10 0.39 0.45 0.28 0.51
Mild 1/14 1/14 0/12 0/10 0.52 — 0.54 0.58
Moderate 1/14 0/14 0/12 1/10 0.50 0.45 0.54 0.42
Steatosis
Absent 14/14 14/14 0/12 0/10 — — 10
 7 5 10
 7
Mild (0–30%) 0/14 0/14 8/12 8/10 — 0.30 3 10
 4 6 10
 5
Moderate (30–60%) 0/14 0/14 4/12 2/10 — 0.30 0.03 0.16
High glycogen content
(grading Z2)
6/14 9/14 8/12 9/10 0.16 0.19 0.15 0.15
aMeans were compared using the Student’s t-test
Dichotomous variables were compared using the Fisher’s exact test
Table 2 Patients (recipients) characteristics before receiving IP or non-IP livers
Non-steatotic allografts Steatosic allografts
Variable
IP (n¼14)
group I
Non-IP (n¼14)
group II
IP (n¼12)
group III
Non-IP (n¼10)
group IV
P-value
I versus II
a
P-value
III versus IV
a
P-value
I versus III
a
P-value
II versus IV
a
Age of recipients (years) 50±14 45±14 47±12 45±13 0.38 0.68 0.55 0.89
Gender (M/F) 8/6 9/5 10/2 9/1 0.28 0.43 0.13 0.15
Etiology
Alcoholic cirrhosis 2/14 2/14 4/12 3/10 0.40 0.35 0.20 0.26
HBV cirrhosis 3/14 3/14 1/12 1/10 0.35 0.52 0.29 0.34
HCV cirrhosis 4/14 4/14 3/12 3/10 0.32 0.77 0.32 0.64
Others 5/14 5/14 4/12 3/10 0.30 0.73 0.70 0.33
aMeans were compared using the Student’s t-test
Dichotomous variables were compared using the Fisher’s exact test
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Cell Death and Disease(33 days versus 29 days) were observed between the 10
steatotic and the 14 non-steatotic grafts recipients (Table 4).
No differences in the incidence of acute rejection (AR 6/10
versus 5/14) nor in rejection activity index were observed
(Table 4). However, a statistically signiﬁcant increase in the
incidence of chronic rejection (CR) was observed in recipients
of steatotic grafts compared with recipients of non-steatotic
grafts (7/10 versus 2/14; Po0.01), whereas no differences in
severity of ductopenia was observed (Table 4).
Histological changesinlivers followingtransplantationwere
analysed. Necrotic cells associated with polymorphonuclear
inﬁltrate were observed in centrolobular areas, throughout the
lobule and periportal spaces. Surgical necrosis was more
frequently observed in patients receiving steatotic grafts
compared with patients receiving non-steatotic grafts (10/10
versus 9/14 Po0.05; Figure 1, Table 5). However, no
differences in necrotic index was observed between the two
groups (Table 5). Apoptotic cell death was evaluated by
activated caspase 3 immunostaining. Apoptotic cells were
mostly detected in centrolobular areas in both steatotic and
non-steatotic hepatocytes (Figure 2a). In particular, activated
caspase 3 was more frequently detected in patients receiving
steatotic grafts compared with non-steatotic grafts (3/10
versus 0/14; P¼0.059).
Effects of IP on clinical and histological outcomes of
patients receiving steatotic allografts. IP did not
signiﬁcantly change transaminase peaks and day 5 levels
in recipients of steatotic allografts. In particular, mean AST
and ALT peaks were 881 and 795IU/l in IP graft recipients
compared with 862 and 728IU/l in non-IP graft recipients.
Mean AST and ALT day 5 levels were lower, but not
signiﬁcantly, in IP graft recipients compared with non-IP graft
recipients (55 and 222IU/l versus 139 and 423IU/l,
Table 3 Surgical data during liver transplantation in patients receiving a IP and non-IP allograft
Non-steatotic allografts Steatosic allografts
Variable
IP (n¼14)
group I
Non-IP (n¼14)
group II
IP (n¼12)
group III
Non-IP (n¼10)
group IV
P-value
I versus II
a
P-value
III versus IV
a
P-value
I versus III
a
P-value
II versus IV
a
Allograft weight (g) 1333±192 1533±403 1622±494 1540±314 0.11 0.67 0.06 0.96
Portal ischemic time (min) 435±127 476±151 424±134 429±76 0.44 0.91 0.83 0.38
Arterial ischemic time (min) 36±25 35±24 50±22 40±15 0.88 0.26 0.16 0.56
Blood units 8.1±10.2 5.9±5.2 7.8±11.1 7.5±9.2 0.46 0.94 0.94 0.58
Surgical complications
(vascular or biliary)
3/14 2/14 3/12 3/10 0.34 0.35 0.35 0.27
aMeans were compared using the Student’s t-test
Dichotomous variables were compared using the Fisher’s exact test
Table 4 Clinical data during liver transplantation in patients receiving a IP and non-IP allograft
Non-steatotic allografts Steatosic allografts
Variable
IP (n¼14)
group I
Non-IP (n¼14)
group II
IP (n¼12)
group III
Non-IP (n¼10)
group IV
P-value
I versus II
a
P-value
III versus IV
a
P-value
I versus III
a
P-value
II versus IV
a
Hepatic function
AST at day 5 (IU/l) 42±33 79±57 55±40 139±164 0.047 0.10 0.37 0.22
ALT at day 5 (IU/l) 82±39 247±194 222±246 423±409 0.005 0.17 0.046 0.17
AST peak (IU/l) 235±189 458±308 881±1323 862±762 0.029 0.96 0.08 0.09
ALT peak (IU/l) 187±94 577±361 795±796 728±724 0.0006 0.84 0.009 0.51
PT (%) at day 5 61±13 67±10 63±20 68±9 0.18 0.48 0.73 0.74
Bilirubin at day 7 (mmol/l) 46±44 38±21 106±148 78±45 0.55 0.57 0.16 0.007
Hospitalization
Intensive care unit stay (days) 12±71 1 ±61 5 ±10 12±5 0.67 0.42 0.47 0.59
Total stay in hospital (days) 28±82 9 ±13 52±43 33±9 0.70 0.18 0.049 0.53
Retransplantation 1/14 1/14 0/12 0/10 — — 0.52 0.52
Rejection
Acute rejection 2/14 5/14 2/12 6/10 0.15 0.048 0.40 0.17
Rejection activity index
(mean±S.D.)
5±1.4 5.2±1.3 5±1.7 4.7±0.9 0.86 0.73 1.00 0.66
Acute rejection delay
(median in month)
0.5 1.25 0.5 2 0.84 0.92 0.99 0.99
Chronic rejection 0/14 2/14 2/12 7/10 0.24 0.017 0.20 0.009
Ductopenia (mean±S.D. in %) — 44.5±15.6 49.7±23.1 36.5±10.2 — 0.15 — 0.22
Chronic rejection delay
(median in month)
— 42 9 36 — 0.09 — 1.00
Follow-up (mean±S.D.
in months)
53±18 60±30 47±27 64±26 0.44 0.16 0.51 0.76
aMeans were compared using the Student’s t-test
Dichotomous variables were compared using the Fisher exact test
Medians were compared with Kolmogorov–Smirnov test
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Cell Death and Diseaserespectively). Lower PT and higher serum bilirubin, although
not signiﬁcantly, were observed in IP grafts compared with
non-IP grafts (Table 4). No signiﬁcant differences in post-
transplantation intensive care unit stays were observed
between the two groups (15 days versus 12 days). Total
hospitalization stay was longer, but not signiﬁcantly different,
for IP graft recipients compared with non-IP recipients
(52 days versus 33 days; Table 4).
Interestingly, IP signiﬁcantly decreased the incidence of
both AR and CR in recipients of steatotic grafts compared
with recipients of non-IP steatotic grafts (2/12 versus 6/10 for
AR and 2/12 and 7/10 for CR; Po0.05; Table 4). However, IP
did not change the rejection activity index, nor severity of
ductopenia in steatotic allografts (Table 4).
Histological examination showed that IP tended to de-
crease the incidence of surgical necrosis in steatotic grafts
(8/12 versus 10/10; P¼0.067). However, no differences in
necrotic index was observed between the two groups
(Table 5). No difference in the detection of activated caspase
3 was observed in IP steatotic livers compared with non-IP
steatotic livers (Table 5).
Effects of IP on clinical and histological outcomes
of patients receiving non-steatotic allografts. IP signiﬁ-
cantly decreased both AST and ALT peak and day 5 levels
in non-steatotic allografts recipients. In particular, mean AST
and ALT peak were 235 and 187IU/l in recipients of IP livers
compared with 458 and 577 in recipients of non-IP livers
Figure 1 Representative images of different grades of necrosis. (a) Absence of necrosis ( 200). (b) Mild necrosis: few foci of polymorphonuclear cells (arrows) can be
observed through the lobule surrounding few necrotic hepatocytes ( 200). (c) Moderate necrosis: some foci of polymorphonuclear cells can be observed around the section
of the centrolobular vein (CLV) associatedto some necrotichepatocytes( 200). (d) Severe necrosis: largenecro-inﬂammatory areawith bridging betweentwo centrolobular
veins (CLV;  200)
Table 5 Histological and immunohistochemical and analysis on post-reperfusion livers
Non-steatotic allografts Steatosic allografts
Variable
IP (n¼14)
group I
a
Non-IP (n¼14)
group II
IP (n¼12)
group III
Non-IP (n¼10)
group IV
P-value
I versus II
b
P-value
III versus IV
b
P-value
I versus III
b
P-value
II versus IV
b
Surgical necrosis (presence) 9/14 9/14 8/12 10/10 0.30 0.067 0.32 0.047
Absent 5/14 5/14 4/12 0/10 0.30 0.067 0.32 0.047
Mild 7/14 7/14 5/12 7/10 0.29 0.15 0.28 0.21
Moderate 1/14 1/14 2/12 3/10 0.52 0.30 0.36 0.16
Severe 1/14 1/14 1/12 0/10 0.52 0.54 0.52 0.58
Necrotic index 0.71±0.67 0.67±0.61 0.80±0.71 0.97±0.32 0.85 0.50 0.75 0.17
Activated caspase 3 0/12 0/14 1/12 3/10 — 0.20 0.50 0.059
Beclin 1 2/12 0/14 9/12 2/10 0.20 0.015 0.006 0.16
LC3 2/12 2/14 9/12 3/10 0.40 0.046 0.006 0.26
Beclin 1+ LC3 1/12 0/14 7/12 2/10 0.46 0.071 0.014 0.16
aIn all, 12 parafﬁn blocks were available for group I to allow further immunohistochemical analysis
bMeans were compared using the Student’s t-test
Dichotomous variables were compared using the Fisher’s exact test
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Cell Death and Disease(Po0.05 and Po0.01 for AST and ALT peaks, respectively).
Mean AST and ALT day 5 levels were 42 and 82IU/l in
recipients of IP livers compared with 79 and 247IU/l in
recipients of non-IP livers (Po0.05 and Po0.01 for AST and
ALT day 5 levels, respectively). Lower PT and higher serum
bilirubin were observed, although not signiﬁcantly, in IP
grafts compared with non-IP grafts (Table 4). No signiﬁcant
difference in post-transplantation intensive care unit stays
(12 days versus 11 days) or total hospitalization stays
(28 days versus 29 days) was observed between the IP or
non-IP non-steatotic graft recipients (Table 4).
No difference in the incidence of AR or CR was observed
in these two groups (2/14 versus 5/14 for AR and 0/14 versus
2/14forCR),aswellasinrejectionactivityindexorductopenia
severity (Table 4).
Histological examination did not show any difference in the
incidence or severity of surgical necrosis neither in necrotic
index (Table 5). No apoptotic cells were detected either in IP
nor in non-IP biopsies (Table 5).
IP activates autophagy in steatotic allografts. As we
previously showed that autophagy is activated by IP in
steatotic and peliotic livers treated by chemotherapy,
16 we
investigated the presence of autophagy biomarkers in post-
reperfusion biopsies of this series to evaluate the potential
role of autophagy in steatotic livers.
The presence of autophagy markers was assessed by
immunohistochemical detection of beclin-1 and LC3, these
two proteins being essential for the macroautophagic process
and, respectively, representing an early and a late marker of
autophagy.
17 Hepatocytes showing positive staining for both
proteins were found mainly in the centrolobular areas,
although some positive hepatocytes were observed through-
out the lobule (Figures 2b and c). Beclin-1 and LC3 staining
were rarely observed in post-reperfusion non-steatotic livers.
In particular, only one IP non-steatotic liver was positive for
both protein stains, whereas 7/12 IP steatotic livers showed
positive staining for both beclin-1 and LC3 (Po0.05; Table 5).
Double-positive staining for beclin-1 and LC3 was more
frequently observed in IP steatotic livers compared with non-
IP steatotic livers, although the results did not reach statistical
signiﬁcance (7/12 versus 2/10; P¼0.07; Table 5). When
we considered only immunohistochemical-positive biopsies,
we observed a statistically signiﬁcant increased number of
beclin-1-positive cells in IP steatotic livers compared with
non-IP steatotic livers (Figure 3). Interestingly, we observed
an inverse correlation between the number of LC3-positive
cells and the necrotic index in IP steatotic livers, whereas no
correlation was observed in the other groups. No correlation
between the numberof beclin-1-positive cellsand the necrotic
index was observed (Figure 3).
Discussion
In this study, we showed that IP may be beneﬁcial for both
patients receiving either steatotic or non-steatotic allografts,
although biological mechanisms mediating IP effects did
differ. IP tended to reduce parenchyma necrosis and
subsequent graft rejection incidence in recipients of steatotic
grafts. The activation of autophagy could have an important
role to ensure cell homeostasis, and limit necrosis and graft
rejection in steatotic livers.
Ischemiawasmoredeleteriousinsteatoticgraftscompared
with non-steatotic livers as shown by transaminase levels
after transplantation and the presence of surgical necrosis in
post-reperfusion biopsies of non-IP livers. Our results are in
accordance with previous observations in human or experi-
mental liver surgery.
4,18 Chronic necrosis, generally asso-
ciated with lower ATP levels
19 and increased inﬂammatory
response in the parenchyma,
20 could explain that steatotic
livers are less resistant to I/R injuries.
4,18
The main parameter considered to assess I/R injury was
serum transaminases level. However, contrasting results
were published. The discrepancies in the signiﬁcance of
transaminases values can be attributed to different sample
timing after transplantation and to high interpatient variability,
particularly in marginal grafts such as steatotic livers, as we
can observe here, or grafts from donors 460 years of age.
15
Indeed, we showed that IP signiﬁcantly decreased transami-
nases levels in non-steatotic livers, whereas a nonsigniﬁcant
decrease was observed in IP steatotic liver. Moreover, the
groups of patients with improved transaminase levels did not
beneﬁt from shorter hospitalization stays, as also observed
in other studies.
21,22 Therefore, more accurate biological
markers are needed to better assess I/R injuries and the
subsequent effects of IP.
Figure 2 Assessmentofactivatedcaspase3,beclin-1andLC3insteatoticpreconditioned livers.(a)Activatedcaspase3 expression inthehepatocytes ofa centrolobular
region(arrows;  400). Hepatocytesexpressingactivatedcaspase3 circumscribedwithinthedashedlines are shown enlargedin theinset( 1000). (b) Beclin-1expression
in the hepatocytes located in a centrolobular region and also in the lobule ( 400). Centrolobular hepatocytes expressing beclin-1 circumscribed within dashed lines are
shown enlarged in the inset ( 1000). (c) LC3 expression in the hepatocytes located in a centrolobular region and also in the lobule ( 400). Centrolobular hepatocytes
expressing LC3 circumscribed within dashed lines are shown enlarged in the inset ( 1000)
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Cell Death and DiseaseSimilarly, the decrease of apoptosis has been reported as a
biological protective mechanism triggered by IP.
23 It has been
mostly assessed by TUNEL assay or caspase 3 or Bcl-2
expression levels evaluation. However, results were not
always conclusive.
15,16,23 This can be because of the use of
the TUNEL assay that can not discriminate between
apoptosis or necrosis cell death,
9 or to the comparison of
groups of biopsies that included steatotic livers or livers from
donors over the age of 60. Indeed, steatotic livers have been
reported to have higher levels of oxidative or nitrosative
radicals with subsequent oxidized lipids and proteins,
24 and
consequently lower intracellular ATP levels, thus favoring
necrotic cell death following I/R injury.
24,25 In our study, we
observed that steatotic livers frequently exhibited necrosis
although non-steatotic livers did not. Interestingly, IP tended
to decrease the incidence of necrosis without changing
apoptosis in IP steatotic livers. We can note, as in other
studies,
15,26 that apoptosis assessed by caspase 3 activation
was not a major mechanism triggered by I/R. Few hepato-
cytesexhibitedcaspase3activation.Wecanhypothesizethat
other apoptotic pathways could be activated or that apoptosis
wascontrolled.Recently,autophagyhasbeendescribedtobe
activated in stress conditions to ensure cell survival by limiting
necrosis or apoptosis in vivo.
27 Autophagy is a catabolic
pathwaytriggered followingvariousstressconditions,suchas
starvationortransienthypoxia,andaimedtorestoreadequate
intracellular ATP and aminoacids levels and to eliminate
damaged organelles.
28,29 It is reported that autophagy cross-
talks with apoptotic and necrotic cell death pathways,
17 and
that activation of autophagy may favour cellular survival by
decreasing reactive oxygen species production.
30 In other
cellular contexts, autophagy has been shown to retard cell
death by suppressing ER stress.
31 Actually, ER stress has
been recently described to have a role in the pathogenesis of
liver steatosis
32,33 and ER stress inhibition has been shown to
be protective under I/R in an experimental model of steatotic/
non-steatotic partial hepatectomy.
34 Thus, we can speculate
that in our context, activation of autophagy may be involved in
ER stress attenuation in steatotic livers, and that the modula-
tion of autophagy and ER stress can have beneﬁcial effects
in liver pathologies. Accordingly, our group has described
that IP can trigger autophagy to switch on/off necrosis
and/or apoptosis in steatotic or peliotic livers from patients
formerly treated by several courses of chemotherapy.
16
In this study, the decreased trend of incidence of necrosis
that we observed was associated with a signiﬁcant increased
expression of autophagy markers in steatotic livers. Thus,
the induction of autophagy, especially in IP steatotic livers,
was in favor of the restoration of sufﬁcient energetic levels
and aminoacids availability in injured hepatocytes to prolong
their survival under I/R stress. It is noteworthy that high ATP
levels have been correlated with better post-transplantation
outcomes.
35,36
Tissue necrosis and vascular injury caused by I/R has been
associated with an increased risk of acute and chronic graft
rejection.
37 Interestingly, in our study IP signiﬁcantly de-
creased mild AR and mild CR incidences only in recipients of
steatotic livers. A decrease in AR was previously observed in
recipients of IP liver in other studies
13–15 and in particular
Franchello et al. showed that IP increased survival rates at 6
months in marginal grafts but not in non-marginal grafts
(which had, however, a higher survival rate compared with
marginal livers). The biological mechanism involved in the
decrease graft rejection after IP remains to be elucidated.
However,adecreasedsensitivity innecroticcell deaththatwe
and other authors observed
15 and probably a decreased
inﬂammatory response observed by another group
13 may be
involved. It has been hypothesized that perioperative allograft
injury induced by I/R releases mediators, such as TNFa, IL1a,
HMGB1, and cellular nucleotides, that enhance destructive
adaptive immune responses driving vascular inﬂammation
and production of IL1b within grafted organs.
38 Interestingly,
TNFa signaling, known as a mediator of inﬂammation in liver
and adipose tissue, has been recently shown to be involved
also in NAFLD pathogenesis.
39,40 Thus, the induction of
autophagy may promote cell survival by restoring adequate
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Cell Death and Diseaseintracellular ATP levels and consequently decreasing the
release of inﬂammation mediators by injured cells. In our
clinicalcontext, wecannot conclude whether autophagyhas a
pro-survival role or an ATP restoring function, but a better
understanding of autophagy activation during IP may lead
clinical improvements in post-transplantation outcomes of
patients receiving steatotic grafts.
Patients and Methods
Study population and experimental design. Among the patients who
underwent a liver transplantation in our institution from 2000: (1) in an elective
situation, (2) with a whole deceased donor liver, (3) from a donor without cardiac
arrest or severe hemodynamical instability before retrieval, we analyzed patients
who received an IP steatotic graft (n¼12) and we compared them with age-
matched patients receiving non-IP steatotic liver grafts (n¼10), IP non-steatotic
liver grafts (n¼14) or non-IP non-steatotic liver graft (n¼14). Only patients
receiving a graft from a donor staying o4 days in an intensive care unit and not
having an alcohol-induced accident were included in the study. The mean duration
stay of donors in an intensive care unit was 1.9±1.1 days. The protocol of
preconditioning (10min of portal triad clamping followed by 10min of reperfusion
followedby multiorgan recovery)is thesame as used in theprevious clinicalstudies
performed at our institution.
12,21 All post-reperfusion biopsies were taken at the
same time before closure of the abdomen. The protocol was approved by our
center’s investigation and review board, and was always accepted by the teams
recovering other organs. The pre-transplant characteristics of graft donors are
shown in Table 1. I/R injury was evaluated as transaminase peak levels and
transaminase levels 5 days after transplantation (day 5). A routine histological
examination on post-reperfusion livers was performed to assess the degree of
steatosis and surgical necrosis.
Each group was followed until July 2010 in order to evaluate the incidence and
the grading of AR and CR of liver grafts after liver transplantation.
Histological evaluation. Samples were ﬁxed in alcohol–formalin–acetic
acid, embedded in parafﬁn and stained with standard haematoxylin eosin safran
and picrosirius stain. Histological review was made by an experienced pathologist
(MS) without knowledge of the state of IP of the graft or other clinical data. The
reviewconcernedpost-reperfusionsurgicalbiopsies.Histologicalfeatures,including
steatosis and ‘surgical’ necrosis, were assessed semi-quantitatively. Steatosis of
macro and microvacuolar type was graded as mild (0–30%), moderate (30–60%)
or severe (60–100%). Severely steatotic livers are discarded and not used for
transplantation. When mixed steatosis was observed, the overall degree was
calculated adding the macro and microvacuolar degrees. ‘Surgical’ necrosis
was deﬁned as patchy necrosis associated with polymorphonuclear inﬁltrate
and graded as mild (score¼1), moderate (score¼2) and severe (score¼3).
To assess a necrotic index, the mean score between lobular, periportal and
perivenous necrosis was calculated for each biopsy. The review also concerned
liver biopsies performed in the recipient after liver transplantation, especially in
order to assess the presence of AR and CR, both graded according to the
relevant Banff classiﬁcations.
22 A rejection activity index was used to score liver
allograft biopsies with AR, whereas severity of ductopenia was used to score liver
allograft biopsies with CR.
Immunohistological procedures. All but two liver samples were available
for immunostaining. Immunohistology was performed on 4mm parafﬁn-embedded
formalin-ﬁxed tissue sections using activated anti-human rabbit caspase 3 (Cell
Signaling, Beverly, MA, USA), anti-human mouse beclin-1 (an early and essential
autophagicprotein;BDBiosciences,FranklinLake,NJ,USA)andanti-humanrabbit
anti LC3 (a late autophagic protein; MBL, Nagoya, Japan) antibodies. Antigen
retrieval was obtained by heat at 971C in a citrate buffer at pH 6 and in Tris-citrate
bufferfor beclin-1andLC3 andat pH 9 with 0.5%saponinefor activatedcaspase 3.
The revelation system was based on a three-step biotin-free immunophosphatase
stain using 5-bromo-4-chloro-3-indolyl phosphate/nitroblue tetrazolium chromogene
substrate (Dako, Glostrup, Denmark) followed by nuclear red counterstaining for
beclin-1 and LC3 detection, whereas it was a one-step biotin free immuno-
peroxidase stain (ImmPress, Vector Laboratories, Burlingame, CA, USA) using
3,3-diamino-benzidinechromogene (Dako) substratefollowedby Hemaluncounter-
staining for activated caspase 3.
Statistical analysis. Results are expressed as mean and standard deviation.
Mean results were compared in the different groups with the help of variance
analysis. Student t-tests after normalization of variables were used to compare two
means. For dichotomous variables, a Fisher exact test was used. Median was used
to compare AR or CR delay. Median results were compared in the different groups
with Kolmogorov–Smirnov tests.
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